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BACKGROUND
The DiGeorge syndrome, the most common of the microdeletion syndromes, affects 
multiple organs, including the heart, the nervous system, and the kidney. It is caused 
by deletions on chromosome 22q11.2; the genetic driver of the kidney defects is 
unknown.
METHODS
We conducted a genomewide search for structural variants in two cohorts: 2080 pa-
tients with congenital kidney and urinary tract anomalies and 22,094 controls. We 
performed exome and targeted resequencing in samples obtained from 586 addi-
tional patients with congenital kidney anomalies. We also carried out functional 
studies using zebrafish and mice.
RESULTS
We identified heterozygous deletions of 22q11.2 in 1.1% of the patients with con-
genital kidney anomalies and in 0.01% of population controls (odds ratio, 81.5; 
P = 4.5×10−14). We localized the main drivers of renal disease in the DiGeorge syn-
drome to a 370-kb region containing nine genes. In zebrafish embryos, an induced 
loss of function in snap29, aifm3, and crkl resulted in renal defects; the loss of crkl 
alone was sufficient to induce defects. Five of 586 patients with congenital urinary 
anomalies had newly identified, heterozygous protein-altering variants, including 
a premature termination codon, in CRKL. The inactivation of Crkl in the mouse model 
induced developmental defects similar to those observed in patients with congenital 
urinary anomalies.
CONCLUSIONS
We identified a recurrent 370-kb deletion at the 22q11.2 locus as a driver of kidney 
defects in the DiGeorge syndrome and in sporadic congenital kidney and urinary tract 
anomalies. Of the nine genes at this locus, SNAP29, AIFM3, and CRKL appear to be 
critical to the phenotype, with haploinsufficiency of CRKL emerging as the main 
genetic driver. (Funded by the National Institutes of Health and others.)
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D
eletions on chromosome 22q11.2 
are the most common cause of the Di-
George syndrome (Online Mendelian In-
heritance in Man [OMIM] number, 188400) and 
the velocardiofacial syndrome (OMIM number, 
192430) and constitute the most common micro-
deletion disorder in humans, with an estimated 
prevalence of 1 in 2000 to 4000 live births.1-3 The 
DiGeorge syndrome is a debilitating, multisys-
temic condition that features (with variable ex-
pressivity) cardiac malformations, velopharyngeal 
insufficiency, hypoparathyroidism with hypocal-
cemia, and thymic aplasia with immune defi-
ciency. Additional phenotypes include neurodevel-
opmental defects and urogenital malformations.4-7 
The long arm of chromosome 22 contains multi-
ple segmental duplications (low-copy repeats) that 
confer a predisposition to genomic rearrange-
ments.8-10 Most frequently, the DiGeorge syn-
drome is caused by a de novo heterozygous dele-
tion of approximately 2.5 mb in length on 
chromosome 22q11.2 between low-copy repeats 
(LCR22) A and D. Less frequently, the syndrome 
is the result of deletions between LCR22 A and B, 
between B and D, or between C and D.5,8,11
Congenital kidney and urinary tract anoma-
lies are present in approximately 30% of the pa-
tients with the DiGeorge syndrome.4,6,12,13 Al-
though some of the hallmarks of this syndrome 
(e.g., heart defects) can be attributed in part to 
haploinsufficiency of TBX1,14-18 the identity of the 
genes that are responsible for such congenital 
kidney and urinary tract anomalies remains un-
known.
Me thods
Study Samples
We studied samples obtained from 2666 patients 
affected by congenital kidney and urinary tract 
anomalies at 26 international centers, along with 
additional samples provided by the Chronic Kid-
ney Disease in Children Study (see the Methods 
section and Table S1 in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org). We performed genomewide geno-
typing for analysis of copy-number variations in 
2080 of these samples. Among an additional 586 
patients with congenital kidney and urinary tract 
anomalies, we performed either whole-exome se-
quencing (in 60 samples) or targeted next-gener-
ation sequencing and Sanger validation (in 526 
samples). All the patients provided written in-
formed consent. The study was approved by the 
institutional review board at each site. (Descrip-
tions of the patients, analyses of convolution de-
fects in zebrafish, analysis of tissue localization 
in the patients and zebrafish, and the generation 
and analysis of a mouse model are provided in the 
Methods section in the Supplementary Appendix.)
Genetic Analyses
Using samples obtained from 2080 patients with 
congenital kidney and urinary tract anomalies and 
22,094 controls, we performed genomewide geno-
typing for analysis of copy-number variation by 
means of high-density single-nucleotide polymor-
phism (SNP) microarrays manufactured by Illu-
mina (1820 samples) or Affymetrix (260 samples), 
as described previously.19-21 We also performed 
whole-exome sequencing on samples obtained 
from 60 patients through the Yale Center for 
Mendelian Genomics, as described previously.22-24 
We performed high-throughput next-generation 
sequencing for eight genes in the 370-kb mini-
mal region of overlap for the DiGeorge syndrome 
in samples obtained from an additional 526 pa-
tients using microfluidic polymerase-chain-reac-
tion capture (Fluidigm) coupled with next-gener-
ation sequencing on an Illumina 2500 HiSeq 
system, as described previously.25,26 We subjected 
CRKL coding exons to next-generation resequenc-
ing in samples obtained from 576 unaffected 
controls and from 1152 patients affected by IgA 
nephropathy but with normal results on renal 
ultrasonography. These additional 1728 controls 
were matched with the patients according to their 
ancestral origin and recruitment site.
R esult s
Patients with 22q11.2 Deletions
In a genomewide search for rare copy-number 
variations in a discovery cohort of 1752 patients 
with congenital kidney and urinary tract anoma-
lies, we identified deletions at the chromosome 
22q11.2 locus in 11 patients (0.6%) and in 3 of 
22,094 population controls (0.01%; odds ratio for 
patients versus controls, 46.4; P = 9.7×10−11). An 
analysis of breakpoints indicated that all deletions 
in the 11 patients overlapped with the common 
deletion between LCR22 A and D: 2 patients 
had the classic deletion of DNA between A and D, 
1 patient had a smaller deletion (bounded by 
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B and D), and 8 patients had the smallest dele-
tion, between C and D (Table 1 and Fig. 1, and 
Table S2 in the Supplementary Appendix).
Of the 11 patients, 9 had renal agenesis or 
hypodysplasia, and 2 had an isolated ureteric 
phenotype, findings indicating that the 22q11.2 
locus between LCR22 C and D is critical for hu-
man nephrogenesis and is possibly specific for 
renal agenesis or hypodysplasia (in 9 of 765 pa-
tients [1.2%]). In a replication study involving an 
additional 328 patients with renal agenesis or hy-
podysplasia, we identified 3 (0.9%) with 22q11.2 
deletions, for a total of 14 patients with these 
deletions (Table 1 and Fig. 1). Taken together, we 
identified deletions at this locus in 12 of 1093 
patients (1.1%) with renal agenesis or hypodyspla-
sia, as compared with 3 of 22,094 controls (odds 
ratio, 81.5; P = 4.5×10−14), which implicates dele-
tions at the locus associated with the DiGeorge 
syndrome as the second most common genomic 
disorder of the kidney and urinary tract after the 
17q12 microdeletion associated with the renal 
cysts and diabetes syndrome (Table S2 in the 
Supplementary Appendix).19,27
Of the 14 patients with the 22q11.2 deletion, 
Patients P1, P2, and replication Patient 1 (RP1) 
carried the most frequent deletion between LCR22 
A and D; in Patient P2, the deletion was inher-
ited from the mother, in whom a clinical diag-
nosis of the DiGeorge syndrome had not been 
made. In all the patients, the molecular genetic 
diagnosis preceded a clinical diagnosis of the 
DiGeorge syndrome (in which some but not all 
features of the syndrome were observed) and 
had a direct effect on the patient’s treatment. In 
patients with deletions between LCR22 B and D 
and C and D, additional urinary tract defects con-
sisted of vesicoureteral reflux in 6 patients and 
hypospadia in 1 patient. Extrarenal defects were 
rare and mild in patients with deletions between 
LCR22 B and D and C and D. The deletion be-
tween LCR22 C and D that was identified in 
Patient P10 was also observed in a sibling who 
was affected by left renal agenesis and an unde-
scended testis.
The analysis of the breakpoints in copy-num-
ber variation that was based on SNP array data 
localized the critical region for the phenotype as-
sociated with congenital kidney and urinary tract 
anomalies to a locus of approximately 370 kb, 
which contains nine genes (Fig. 1, and Table S3 
in the Supplementary Appendix). This region ex-
cluded the gene encoding T-box 1 (TBX1), a protein 
that is not expressed in the murine embryonic 
kidney,28 so Tbx1-null mice have normal early 
nephrogenesis (Fig. S2 in the Supplementary Ap-
pendix). Interrogation of the “22q and You” data-
base from the Children’s Hospital of Philadelphia 
identified kidney malformations in 2 of 10 patients 
with the 22q11.2 deletion between LCR22 C and 
D (Table S4 in the Supplementary Appendix). 
Finally, we reexamined the three controls with 
22q11.2 deletions; one carried the typical dele-
tion between LCR22 A and D, one the deletion 
between B and D, and one the deletion between 
C and D. We obtained clinical records for Con-
trol C1, who had Parkinson disease, congenital 
hypoparathyroidism, and advanced chronic kid-
ney disease (Table S5 in the Supplementary Ap-
pendix). Thus, we found a patient with undiag-
nosed DiGeorge syndrome with renal involvement 
among our 22,000 population controls, which 
provided further support for the pathogenicity of 
the 22q11.2 deletion in patients with congenital 
kidney and urinary tract anomalies. After removal 
of this patient from the control data set, the 
strength of association between 22q11.2 deletions 
and renal agenesis or hypodysplasia increased 
further (12 of 1093 patients vs. 2 of 22,093 con-
trols, P = 8.5×10−15; odds ratio, 123.7).
Functional Modeling in Zebrafish
The genetic data suggested that dosage perturba-
tion of one or more of the nine genes in the micro-
deletion on 22q11.2 is a driver of congenital kidney 
and urinary tract anomalies. We had previously 
found that systematic in vivo suppression of ex-
perimentally tractable genes within a deletion 
copy-number variant, coupled with quantitative 
phenotyping, can determine the contribution of 
specific transcripts to disease associated with 
copy-number variation in humans.29-31
We first sought to establish a phenotypic sur-
rogate for congenital kidney and urinary tract 
anomalies in zebrafish embryos. Previous stud-
ies in mice and humans have shown the critical 
role of the gene encoding ret proto-oncogene (RET) 
for kidney development and branching morpho-
genesis.32-35 We therefore injected an established 
morpholino oligonucleotide (MO) against RET 36 
into zebrafish that were engineered to enable 
visualization of the developing nephron and then 
examined the convolution of the pronephros (the 
earliest developmental stage in the zebrafish) at 
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4.5 days after fertilization.37 The injection of 8.0 ng 
of a splice-blocking MO, which suppressed ap-
proximately 80% of wild-type message and in-
duced the inclusion of intron 2, followed by 
staining of embryos with an antibody against 
sodium–potassium ATPase, induced convolution 
defects of the proximal pronephros and an over-
all reduction in the length of the tubules (Fig. S3 
in the Supplementary Appendix). We captured this 
phenotype by measuring the length of the tubule 
corrected for the overall length of the embryonic 
body axis, thus controlling for possible develop-
mental delay due to the mechanical manipula-
tion of embryos (P<0.05 for all comparisons 
between MO knockdown and wild type) (Fig. 2A 
and 2B). This phenotype was specific; not only 
were we able to rescue this anomaly by coinjec-
tion of 200 pg of human capped RET messenger 
RNA (mRNA) (Fig. 2B), but deletions at this locus 
that were mediated by CRISPR–Cas9 also repro-
duced this anomaly in a manner indistinguish-
able from the MO, both qualitatively and quan-
titatively (Fig. 2C and 2D). We therefore proceeded 
to deploy this assay across all testable genes 
within the region of copy-number variation.
First, we used the Basic Local Alignment 
Figure 1. Genomic Organization of Chromosome 22q11.2 and the Deletions Associated with Kidney and Urinary 
Tract Malformations Identified in This Study.
In approximately 90% of the patients with the DiGeorge syndrome, the congenital disorder is caused by a classic 
de novo heterozygous deletion of approximately 2.5 mb in length spanning chromosome 22q11.2 low-copy repeats 
(LCR22) A and D, as shown in blue. Less than 10% of the patients with this syndrome carry the critical 1.5-mb dele-
tion between LCR22 A and B. Shown in red are deletions that were identified in 14 patients who were affected by 
congenital anomalies of the kidney and urinary tract among the 2080 patients who were tested. According to the 
megabase coordinates for the Human Genome 19 release, the proximal and distal breakpoints for the chromosome 
22q11.2 deletions that were identified in the patients are as follows: P1, 18.88 to 21.47 mb; P2, 18.89 to 21.47 mb; 
P3, 20.73 to 21.46 mb; P4, 21.02 to 22.47 mb; P5, 21.05 to 21.47 mb; P6, 21.06 to 21.47 mb; P7, 21.06 to 21.46 mb; 
P8, 21.06 to 21.46 mb; P9, 21.07 to 21.46 mb; P10, 21.08 to 21.47 mb; P11, 21.09 to 21.47 mb; Patient 1 from the 
replication cohort (RP1), 18.88 to 21.46 mb; RP2, 20.74 to 21.46 mb; and RP3, 20.74 to 21.46 mb. The deletion be-
tween LCR22 C and D defines the smallest region of overlap for congenital kidney disease among patients with 
22q11.2 deletions.
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Search Tool (BLAST) algorithm for sequence 
searching, in which we detected orthologues for 
seven of nine genes. RNA sequencing data indi-
cated that all seven genes were expressed in the 
early embryo, between 2 and 4 days after fertil-
ization.38 We therefore designed MOs to knock 
down the expression of these genes and injected 
them into zebrafish reporter lines in parallel with 
the ret–MO as a control. For four of the transcripts 
(lztr1, pi4ka, serpind1, and slc7a4) we observed no 
differences in convolution complexity or length 
of the pronephros between the knockdown zebra-
fish and controls in 26 to 34 embryos, with each 
analysis repeated twice with blinded scoring 
(Fig. S4 in the Supplementary Appendix). In con-
trast, the suppression of crkl expression or interrup-
tion of splicing of aifm3 and snap29 phenocopied 
the pathologic features of RET (Fig. 2A and 2B). 
These phenotypes could be rescued for each of the 
three genes by coinjection with human mRNA 
(Fig. 2B). In addition, deletions of snap29 and crkl 
mediated by CRISPR–Cas9 on the day of fertiliza-
tion induced insertions or deletions in 60 to 80% 
of cells within each mutant embryo (Fig. S5 in the 
Supplementary Appendix). (The gene aifm3 was 
intractable to this method.) Subsequently, the mu-
tant fish fully reproduced the renal disease (Fig. 2C 
and 2D). We observed no renal phenotypes when 
each human mRNA was injected alone, nor did 
we find any other gross morphologic defects in 
embryos subjected to either MO knockdown or 
overexpression at the studied developmental time 
points that might indicate nonspecific toxicity. 
Because kidney morphogenesis could be affected 
by extrarenal defects (e.g., loss of cardiac output 
and collective cell migration of the nephron in-
duced by loss of flow), we analyzed heart func-
tion in both ret and crkl mutants and found no 
effect on the morphologic features or rate of the 
heart. We also found no evidence of kidney cysts, 
which would be expected if cilia-dependent flow 
were to be impaired. Analysis of body length as 
an indication of global-developmental delay 
showed no significant difference between “knocked 
down” zebrafish and control zebrafish (Fig. S6 
in the Supplementary Appendix). Thus, we con-
cluded that the defects we observed were not due 
to the known indirect causes of failed nephron 
convolution in zebrafish and support our use of 
this assay as a screening technique for intrinsic 
kidney defects.
Previous functional dissections of copy-num-
ber variation have revealed a complex genetic ar-
chitecture, in which a single driver may account 
for the induction of disease either alone or in cis 
epistasis with other genes within the copy-num-
ber variation.29-31 We tested this possibility in 
vivo by asking whether the three transcripts in 
zebrafish embryos that induce congenital kidney 
and urinary tract anomalies could interact ge-
netically. For this purpose, we injected embryos 
with subeffective doses of each transcript, with 
the requirement that each dose by itself should 
induce modest or no disease; we then tested all 
possible pairwise combinations. We observed no 
genetic interaction between crkl and either aifm3 
or snap29. In contrast, cosuppression of aifm3 with 
Figure 2 (facing page). Functional Modeling of the  
DiGeorge Syndrome Terminal Deletion Genes  
Associated with Kidney and Urinary Tract  
Malformations.
Panel A shows zebrafish larvae 4.5 days after fertiliza-
tion, in which the proximal tubule is folded into a hair-
pin structure, displaying proper anterior convolution 
in noninjected control embryos (staining with anti-
body against sodium–potassium ATPase). Knockdown 
of ret, aifm3, crkl, and snap29 by the injection of 8.0 ng 
of a splice-blocking morpholino oligonucleotide (MO) 
against RET resulted in major convolution defects, 
which are apparent by the failure of the anterior por-
tion of the pronephros (the earliest developmental 
stage in the zebrafish) to progress, along with an over-
all reduction in the length of the tubules. Panel B 
shows the relative length of the pronephros, which 
was defined as the ratio of the length of the proneph-
ros (a) to the length of the body axis (b), in individual 
larvae (inset). The number of replicate measurements 
were as follows: control or sham-injected control, 177 
in Panel A and 68 in Panel B; ret-MO, 50; ret-
MO+mRNA, 42; aifm3-MO, 38; aifm3-MO+mRNA, 42; 
crkl-MO, 43; crkl-MO+mRNA, 58; snap29-MO, 48; 
snap29-MO+mRNA, 39; ret-gRNA+Cas9, 44; crkl-
gRNA+Cas9, 31; and snap29-gRNA+Cas9, 41). Mor-
phant phenotypes could be rescued by the coinjection 
of each respective human messenger RNA (mRNA).  
In each box-and-whisker plot, the horizontal line rep-
resents the median, the top and bottom of the boxes 
the interquartile range, and the I bars the minimum 
and maximum values. Panel C shows embryos that 
have been injected with CRISPR–Cas9 and that are re-
producing the convolution defects observed in the 
morphant embryos. Guide RNA (gRNA) that targeted 
each respective gene was coinjected with purified 
Cas9 protein, and the relative length of the proneph-
ros was measured in founders, as shown in Panel D. 
In Panels B and D, a single asterisk indicates P<0.05, 
two asterisks P<0.01, and three asterisks P<0.001.  
WT denotes wild type.
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snap29 phenocopied the convolution defect of 
strong morphants and CRISPR mutants, which 
suggested a contributory role to the copy-number 
variation pathology. This interaction was specific 
and not due to toxicity caused by the presence of 
multiple MOs, since it could be rescued by coin-
jection of SNAP29 mRNA (Figs. S7 and S8 in the 
Supplementary Appendix).
Whole-Exome and Targeted Sequencing  
of CRKL
We asked whether sporadic patients with con-
genital kidney and urinary tract anomalies might 
have loss-of-function lesions in any of the nine 
genes included in the minimal region of overlap 
for the kidney defects of the DiGeorge syndrome. 
We first queried exome-sequencing data from 
60 patients with renal agenesis or hypodysplasia. 
None of the genes showed excess burden of rare 
truncating mutations as compared with controls 
(Table S6 in the Supplementary Appendix). LZTR1, 
P2RX6, and SLC7A4 have a high frequency of loss-
of-function mutations (defined as premature ter-
mination, splicing, and frameshift mutations), a 
prevalence that approaches or exceeds that of 
such anomalies in the general population. Con-
versely, SERPIND1, SNAP29, CRKL, and THAP7 
carry loss-of-function mutations in no more than 
2 of 10,000 persons. Among more than 60,500 
publicly available population controls from the 
Exome Aggregation Consortium (ExAC) database 
(exac.broadinstitute.org), only 1 had a high-qual-
ity loss-of-function variant in CRKL, which ranks 
in the top second percentile in the genome for 
haploinsufficiency — in other words, there is a 
high probability of a detrimental effect on pheno-
type when only one copy of the gene is deleted. 
This finding suggests that loss-of-function vari-
ations in CRKL have deleterious effects on ge-
netic fitness (Table S3 in the Supplementary 
Appendix).39
We also performed targeted next-generation 
resequencing of all 107 coding exons of PI4KA, 
SERPIND1, SNAP29, CRKL, AIFM3, THAP7, P2RX6, 
and SLC7A4 in 526 patients with renal agenesis or 
hypodysplasia. We identified six loss-of-function 
variants in 11 patients: two in SERPIND1, one in 
CRKL, one in AIFM3, and two in P2RX6 (in 7 pa-
tients) (Table S7 in the Supplementary Appendix). 
Loss-of-function mutations in SERPIND1 have been 
associated with a mendelian clotting disease (hep-
arin cofactor II deficiency) that has no known 
associations with kidney and urinary tract devel-
opment.40 In contrast, the CRKL truncating mu-
tation, p.Q31*, was found in a patient (P13) with 
isolated unilateral renal agenesis and was pre-
dicted to result in haploinsufficiency. We also 
identified four additional missense variants that 
were absent from the ExAC database, that were 
conserved across vertebrates, and that were pre-
dicted to affect protein structure and function 
(Table S8 and Figs. S9 and S10 in the Supple-
mentary Appendix).
Whole-exome sequencing of DNA obtained 
from P13 did not show pathogenic mutations in 
genes that had previously been implicated in 
congenital kidney and urinary tract anomalies or 
loss-of-function variants in newly plausible can-
didates (Table S9 in the Supplementary Appen-
dix). Finally, because of the formal possibility 
that the discovered CRKL variants were popula-
tion-specific polymorphisms, we performed tar-
geted resequencing on samples obtained from 
576 additional controls and from 1152 patients 
with IgA nephropathy and normal results on 
renal ultrasonography who were matched with 
our patients according to ethnic background and 
recruitment site. All CRKL variants were absent 
in the more than 60,500 population controls from 
the ExAC database and in the 1728 controls. Ag-
gregating our sequencing data and performing 
burden tests between our 586 patients with con-
genital kidney and urinary tract anomalies and 
33,352 European controls from ExAC or 1728 
ethnically and geographically matched controls 
showed significant excess of rare functional CRKL 
variants in our patients (P = 3.7×10−3 by Fisher’s 
exact test for the comparison with ExAC controls; 
odds ratio, 5.2; and P = 4.9×10−3 for the compari-
son with matched controls; odds ratio, 14.8) (Ta-
ble S10 in the Supplementary Appendix).
Expression and Functional Studies of CRKL
We performed mRNA and protein expression stud-
ies in relevant tissues and examined a mouse 
model with a Crkl mutation. In humans, CRKL 
protein showed mild, diffuse cytoplasmic ex-
pression in both ureteric bud and metanephric 
mesenchyme derivatives during the sixth week 
of fetal development (Fig. S11A in the Supple-
mentary Appendix). At week 21, CRKL was de-
tected only in proximal tubules and collecting 
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Figure 3. Localization of Crkl in Developing Urinary Tracts in Mice and Zebrafish and Phenotypes of Crkl Knockout Mice.
Panel A shows immunostaining for Crkl in kidney obtained from a transgenic mouse on embryonic day E15.5, in which Six2 has been 
tagged with enhanced green fluorescent protein (GFP), with specific Crkl staining of the ureteric bud (in red) surrounded by Six2-posi-
tive cap mesenchyme cells (in green) (subpanel a). A magnified field shows ureteric-bud branching within condensing metanephric 
mesenchyme (subpanel b). Panel B shows specific pronephros expression of crkl in zebrafish, as shown by colocalization after staining 
with antibody against sodium–potassium ATPase. In the orientation symbol, D denotes dorsal, V ventral, C caudal, and R rostral. Panel C 
shows images of negative controls (i.e., fish treated with fluorophore-conjugated secondary antibodies only). In Panels B and C, the 
scale bars represent 100 µm. In a mouse model that targets Crkl exon 2, three crosses with transgenic Cre-recombinase mice were creat-
ed to effect the deletion of exon 2 in specific compartments: E2a-Cre for global knockout, Six2-Cre in the cap mesenchyme, and Hoxb7 
in the structures derived from ureteric buds. Panel D shows tissue from a Six2-Cre mouse in which duplication of the right kidney is ac-
companied by an irregular, dysplastic pattern or ureteric-bud branching on embryonic day E15.5. Panel E shows tissue from an E2a-Cre 
mouse in which a single kidney with duplicated ureters (arrowheads) is accompanied by failure of medullary and renal papillary develop-
ment on day E14.5. Panel F shows tissue from a Six2-Cre mouse, in which the kidney is hydronephrotic with dilated pelvis, absence of 
medullary architecture, and several microcystic glomeruli and tubules on day E15.5.
D
a
b
Duplicated Mouse Kidney
C Control
Embryonic Mouse Kidney
Crkl Na-K ATPase
Negative
crkl Merge
Six2
Crkl
Six2
Expression of crkl in ZebrafishBA
E Mouse Kidney with Duplicated Ureters F Hydronephrotic Mouse Kidney
100 µm 100 µm 100 µm
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tubules at the apical side of epithelial cells (Fig. 
S11B in the Supplementary Appendix). In the kid-
ney of a 1.5-year-old boy, we observed abundant 
CRKL expression in the proximal and collecting 
tubules at the apical side, along with diffuse cy-
toplasmic signaling in glomerular endothelial 
cells, podocytes, Bowman’s capsule, and distal 
tubules (Fig. S11C in the Supplementary Appen-
dix). The expression of SNAP29 and AIFM3, al-
though present at very low levels in zebrafish 
pronephros (not shown), was seen in the urinary 
tract in fetuses and children (Figs. S12 and S13 
in the Supplementary Appendix).
In the mouse kidney on embryonic day E15.5, 
Crkl showed specific expression in structures de-
rived from the ureteric bud and, occasionally, in 
S-shaped bodies and developing proximal tubules 
(Fig. 3A, and Fig. S14 in the Supplementary Ap-
pendix). In zebrafish, crkl was specifically ex-
pressed in the pronephros (Fig. 3B and 3C). RNA 
studies that were performed with the use of flow 
cytometry and cell sorting, along with in situ hy-
bridization, confirmed that crkl was expressed in 
the pronephric convoluted tubule and proneph-
ric duct (Figs. S15 and S16 in the Supplementary 
Appendix).
Finally, we engineered a mouse model that 
targets Crkl exon 2. We generated three different 
crosses with transgenic Cre-recombinase mice to 
effect the deletion of exon 2 in specific compart-
ments: E2a-Cre for global knockout, Six2-Cre in 
the cap mesenchyme, and Hoxb7 in the ureteric 
bud–derived structures. We analyzed four litters 
(one E2a, one Hoxb7, and two Six2) at embryonic 
days E14.5 through E15.5. We observed develop-
mental anomalies in the kidney and urinary tract, 
including bilaterally duplicated kidneys, duplicat-
ed ureters, ureteric bud–branching defects, dys-
plastic features, hydronephrosis, microcystic tu-
bules and glomeruli, and tubular and glomerular 
capsule dilatation, in eight mice (Fig. 3D, 3E, 
and 3F, and Fig. S17 in the Supplementary Ap-
pendix). We observed phenotypes related to con-
genital kidney and urinary tract anomalies in 
embryos that were heterozygous and those that 
were homozygous for the targeted deletion.
Discussion
We determined that deletions in the telomeric 
22q11.2 classic region are associated with spo-
radic congenital kidney and urinary tract anom-
alies and renal disease in the DiGeorge syndrome. 
Correlations between genotype and phenotype 
suggest that these variants are specific for kid-
ney parenchyma defects (i.e., renal agenesis or 
hypodysplasia), rather than ureteric and lower 
urinary tract disease. However, the presence of 
these variants may be an indication of kidney dis-
ease in persons with apparently isolated ureteric 
defects, since the two patients with obstructive 
uropathy and vesicoureteral reflux whom we iden-
tified in this study showed renal insufficiency. We 
observed that the 22q11.2 deletions were present 
in 1.1% of our sample of 1093 patients with renal 
agenesis or hypodysplasia, which suggests that 
such deletions constitute the second most com-
mon structural variant associated with congeni-
tal kidney and urinary tract anomalies after the 
17q12 deletion that causes the renal cysts and dia-
betes syndrome, which we identified in 2.2% of 
patients with renal agenesis or hypodysplasia from 
the same cohort. Our data also support the hy-
pothesis that 22q11.2 microdeletions are medically 
actionable variants that confer a predisposition to 
renal hypodysplasia and kidney disease.
A review of the literature indicates the pres-
ence of kidney and urinary tract defects in about 
one third of the patients with chromosome 
22q11.2 deletions spanning LCR22 B and D or C 
and D,5,41 a prevalence that is nearly identical to 
that of kidney and urinary tract defects among 
patients with the DiGeorge syndrome caused by 
the typical 22q11.2 deletions spanning LCR22 A 
and D.4,6,42 These observations, together with our 
data, strongly suggest that the kidney disease as-
sociated with the DiGeorge syndrome is attribut-
able largely to haploinsufficiency of one or more 
genes located between LCR22 C and D.
Genetic interaction studies using zebrafish sug-
gested a complex genetic architecture, in which 
haploinsufficiency of crkl had a potent detrimental 
effect on renal development, whereas knockdown 
of its flanking genes, aifm3 and snap29, generated 
the phenotype only with cosuppression. Consis-
tent with these data, we found deleterious CRKL 
variants, including a premature truncating allele, 
in approximately 1% of the patients with sporadic 
congenital renal agenesis or hypodysplasia. We 
obtained other molecular data in humans, mice, 
and zebrafish that supported the role of CRKL in 
urinary tract development.
CRKL encodes an adapter protein that regulates 
intracellular signaling transduction from multi-
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ple growth factors, including the fibroblast growth 
factors,43 which are key regulators of kidney and 
urinary tract development.44,45 Inactivation of Crkl 
in mice recapitulates some of the phenotypes of 
the DiGeorge syndrome, in particular cardiac mal-
formations,46,47 but the kidney phenotype in the 
mutant embryos had not hitherto been studied. 
We observed that genetic inactivation of Crkl in 
the mouse model results in developmental phe-
notypes of the kidney and urinary tract that re-
semble congenital anomalies in the human uri-
nary tract.
We suggest that CRKL mutations sensitize the 
genetic background and contribute to the pene-
trance of congenital kidney and urinary tract 
anomalies in patients with the DiGeorge syn-
drome. It is possible that other genes within or 
outside the locus of the DiGeorge syndrome and 
22q11.2 deletions might also be involved. Two of 
the genes in the minimal region were refractory 
to our studies, and it is possible that the deletion 
copy-number variant affects the expression of 
genes across the chromosome or elsewhere in the 
genome, as has been shown for other copy-num-
ber variants.48
In conclusion, our approach provides support 
for the causal role of CRKL in the pathogenesis of 
kidney developmental defects. Such defects occur 
specifically in the context of the DiGeorge syn-
drome and 22q11.2 deletions and, more broadly, 
in sporadic congenital kidney and urinary tract 
anomalies.
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